- Home
- SLN vs MNTK Comparison
SLN vs MNTK Comparison
Compare SLN & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- MNTK
- Stock Information
- Founded
- SLN 1994
- MNTK 1980
- Country
- SLN United Kingdom
- MNTK United States
- Employees
- SLN N/A
- MNTK N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- MNTK Natural Gas Distribution
- Sector
- SLN Health Care
- MNTK Utilities
- Exchange
- SLN Nasdaq
- MNTK Nasdaq
- Market Cap
- SLN 345.3M
- MNTK 288.8M
- IPO Year
- SLN N/A
- MNTK 2021
- Fundamental
- Price
- SLN $6.67
- MNTK $1.60
- Analyst Decision
- SLN Buy
- MNTK Hold
- Analyst Count
- SLN 6
- MNTK 3
- Target Price
- SLN $39.67
- MNTK $3.33
- AVG Volume (30 Days)
- SLN 212.8K
- MNTK 207.3K
- Earning Date
- SLN 11-06-2025
- MNTK 11-05-2025
- Dividend Yield
- SLN N/A
- MNTK N/A
- EPS Growth
- SLN N/A
- MNTK N/A
- EPS
- SLN N/A
- MNTK N/A
- Revenue
- SLN $25,830,000.00
- MNTK $160,682,000.00
- Revenue This Year
- SLN N/A
- MNTK $2.89
- Revenue Next Year
- SLN N/A
- MNTK $19.36
- P/E Ratio
- SLN N/A
- MNTK N/A
- Revenue Growth
- SLN 40.39
- MNTK N/A
- 52 Week Low
- SLN $1.97
- MNTK $1.56
- 52 Week High
- SLN $8.88
- MNTK $4.96
- Technical
- Relative Strength Index (RSI)
- SLN 55.39
- MNTK 37.09
- Support Level
- SLN $5.91
- MNTK $1.56
- Resistance Level
- SLN $6.62
- MNTK $1.76
- Average True Range (ATR)
- SLN 0.51
- MNTK 0.15
- MACD
- SLN -0.05
- MNTK -0.02
- Stochastic Oscillator
- SLN 81.25
- MNTK 5.45
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.